

CERTIFICATE OF MAILING (37 C.F.R. 1.9)

I hereby certify that this paper (along with any paper referred to as being transmitted therewith) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date:

1/8/03

By:

Winsome Dunn

DOCKET No. 18668.US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Dietnauer, et al.
Christine

SERIAL NO.: 10/087,082

FILED: February 28, 2002

FOR: **Improved Method of Primer-
Extension Preamplification PCR**

EXAMINER: Maupin,

ART UNIT: 1637

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure requirements of 37 C.F.R. §1.56 1.97 and 1.98, Applicants submit herewith a Form-1449, listing accompanying documents which may be material to the examination of this application.

This Information Disclosure Statement is being filed after the mailing date of the first Office action on the merits and before the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first..

Accompanying this transmittal is the fee set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$240.00). The Commissioner is hereby authorized to charge the amount of \$ 240.00, or any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0652. A duplicate copy of this communication is enclosed.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols,

#9188
112416831437

RECEIVED
JAN 15 2003
TECH CENTER 1600/2900



results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Respectfully submitted,

Date: 1/8/03

Charles M. Doyle
Charles M. Doyle
Reg. No. 39,175

Correspondence Address:
Roche Molecular Systems, Inc
1145 Atlantic Avenue
Alameda, CA 94501
Tele: (510) 814-2800
Fax: (510) 814-2973